EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
Fineberg S, Tian X, Makower D, Harigopal M, Lo Y. EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis. Applied Immunohistochemistry & Molecular Morphology 2021, 30: 157-164. PMID: 35262520, DOI: 10.1097/pai.0000000000000998.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersBreast NeoplasmsEnhancer of Zeste Homolog 2 ProteinFemaleHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalRetrospective StudiesTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyEZH2 protein expressionEZH2 expressionBreast cancerHigh-risk triple negative breast cancerLogistic regressionContinuous variablesStratification of outcomesDisease-free survivalProtein expressionTumor-infiltrating lymphocytesHigh EZH2 expressionMultivariable logistic regressionRisk of relapseDevelopment of metastasesLogistic regression analysisPretherapy biopsiesDisease recurrenceMetastatic recurrenceClinicopathologic featuresCancer burdenTumor responseCore biopsy